Ivo Vrobel

Ivo Vrobel

Auto-generated profile, based on publicly available information

Ivo Vrobel

Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2017 in Nature
Verified
Journal Article
Open access
PDF file
ZSZdenek Skrott
Zdenek Skrott
MMMartin Mistrik
Martin Mistrik
KAKlaus Kaae Andersen
Klaus Kaae Andersen
SFSøren Friis
Søren Friis
DMDusana Majera
Dusana Majera
JBJiri Bartek
Jiri Bartek
Cancer incidence is rising and this global challenge is further exacerbated by tumour resistance to available medicines. A promising approach to meet the need for improved cancer treatment is drug repurposing. Here we highlight the potential for repurposing disulfiram (also known by the trade name Antabuse), an old alcohol-aversion drug that has been shown to be effective against diverse cancer types in preclinical studies. Our nationwide epidemiological study reveals that patients who continuously used disulfiram have a lower risk of death from cancer compared to those who stopped using the drug at their diagnosis. Moreover, we identify the ditiocarb–copper complex as the metabolite of disulfiram that is responsible for its anti-cancer effects, and provide methods to detect preferential accumulation of the complex in tumours and candidate biomarkers to analyse its effect on cells and tissues. Finally, our functional and biophysical analyses reveal the molecular target of disulfiram’s tumour-suppressing effects as NPL4, an adaptor of p97 (also known as VCP) segregase, which is essential for the turnover of proteins involved in multiple regulatory and stress-response pathways in cells.

9 August 2016 in Journal of Proteome Research
Verified
Journal Article
Closed access
RKRadana Karlíková
Radana Karlíková
JŠJitka Široká
Jitka Široká
DFDavid Friedecky
David Friedecky
EFEdgar Faber
Edgar Faber
MHMarcela Hrdá
Marcela Hrdá
Tomáš AdamTomáš Adam
Tomáš Adam

14 November 2017 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
JVJan Václavík
Jan Václavík
KCKarlien L. M. Coene
Karlien L. M. Coene
IVIvo Vrobel
Ivo Vrobel
Lukáš NajdekrLukáš Najdekr
Lukáš Najdekr
DFDavid Friedecký
David Friedecký
RWRon Wevers
Ron Wevers

1 August 2016 in Therapeutic Drug Monitoring
Verified
Journal Article
Closed access
IVIvo Vrobel
Ivo Vrobel
HJHana Janečková
Hana Janečková
EFEdgar Faber
Edgar Faber
KBKateřina Bouchalová
Kateřina Bouchalová
KMKateřina Mičová
Kateřina Mičová
Tomáš AdamTomáš Adam
Tomáš Adam
Background: With an increasing number of cancer patients receiving tyrosine kinase inhibitors (TKIs), therapeutic drug monitoring of these molecules is becoming more widespread today. It is mainly based on liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) methods with typical run times of several minutes. In an online solid phase extraction-MS/MS (SPE-MS/MS) system, the chromatography column is replaced with a reusable solid phase extraction (SPE) cartridge and the analysis time is shortened to less than half a minute. The aim of this study was to develop such a method and test the performance of this high-throughput system in the analysis of imatinib (IMA), nilotinib (NIL), and lapatinib (LAP) in human plasma. Methods: Samples were prepared by simple protein precipitation with methanol containing deuterated internal standards. After centrifugation, the supernatant was diluted 10 fold with a mixture of methanol and water (1:1). A C4 cartridge was used for SPE and the analytes were eluted by acetonitrile. All the analytes were measured within a wide calibration range (50–5000 ng/mL for nilotinib and imatinib, 100–10,000 ng/mL for lapatinib). The method was compared with the LC-MS/MS method by the analysis of 176 clinical samples. Results: Intraday and interday inaccuracies within 15% and a coefficient of variation less than 15% were achieved for all the TKIs that were measured. Even though the matrix effects were higher in comparison with LC-MS/MS methods, their effect on the performance of the method was eliminated by the usage of deuterated internal standards. The total run time of the new method was 29 seconds for one analysis and the results were fully comparable with LC-MS/MS. Conclusions: Routine clinical practice requiring high-throughput methods for therapeutic drug monitoring of TKIs may benefit from the online SPE-MS/MS method that provides fast, low-cost analysis, and results that are comparable with conventional methods.

1 June 2017 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
IVIvo Vrobel
Ivo Vrobel
DFDavid Friedecky
David Friedecky
EFEdgar Faber
Edgar Faber
Lukáš NajdekrLukáš Najdekr
Lukáš Najdekr
KMKateřina Mičová
Kateřina Mičová
Tomáš AdamTomáš Adam
Tomáš Adam